Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Case 9% Improvement Relative Risk Case (b) 12% c19early.org/d Li et al. Vitamin D for COVID-19 Sufficiency Favors vitamin D Favors control
Assessment of the Association of Vitamin D Level With SARS-CoV-2 Seropositivity Among Working-Age Adults
Li et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2021.11634
19 May 2021    Source   PDF   Share   Tweet
Cohort study of 18,148 patients in the USA showing low vitamin D associated with COVID-19 PCR+ status before adjustments but not after.
Authors state that "low vitamin D levels were not independently associated with the
risk of seropositivity", however there is significant correlation between some adjustment variables and vitamin D levels in the logistic regression that prevent drawing this conclusion [statisticsbyjim.com]. Details of the logistic regression in the matched sample set are not provided.
Authors analyze only 20ng/mL and 30ng/mL cutoff points, other studies use 10ng/mL (or 12), where more significant differences are typically seen.
risk of case, 8.6% lower, RR 0.91, p = 0.24, high D levels 610 of 13,650 (4.5%), low D levels 290 of 4,498 (6.4%), adjusted per study, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, >20ng/mL, Figure 2.
risk of case, 12.4% lower, RR 0.88, p = 0.07, high D levels 289 of 7,272 (4.0%), low D levels 611 of 10,876 (5.6%), adjusted per study, inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, >30ng/mL, Figure 2.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Li et al., 19 May 2021, retrospective, USA, peer-reviewed, 4 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit